Your browser doesn't support javascript.
loading
Modification of BRCA1-associated breast cancer risk by HMMR overexpression.
Mateo, Francesca; He, Zhengcheng; Mei, Lin; de Garibay, Gorka Ruiz; Herranz, Carmen; García, Nadia; Lorentzian, Amanda; Baiges, Alexandra; Blommaert, Eline; Gómez, Antonio; Mirallas, Oriol; Garrido-Utrilla, Anna; Palomero, Luis; Espín, Roderic; Extremera, Ana I; Soler-Monsó, M Teresa; Petit, Anna; Li, Rong; Brunet, Joan; Chen, Ke; Tan, Susanna; Eaves, Connie J; McCloskey, Curtis; Hakem, Razq; Khokha, Rama; Lange, Philipp F; Lázaro, Conxi; Maxwell, Christopher A; Pujana, Miquel Angel.
Afiliação
  • Mateo F; ProCURE, Catalan Institute of Oncology, Oncobell, Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, 08908, Barcelona, Catalonia, Spain.
  • He Z; Department of Pediatrics, University of British Columbia, Vancouver, BC, V6H 0B3, Canada.
  • Mei L; Department of Pediatrics, University of British Columbia, Vancouver, BC, V6H 0B3, Canada.
  • de Garibay GR; ProCURE, Catalan Institute of Oncology, Oncobell, Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, 08908, Barcelona, Catalonia, Spain.
  • Herranz C; ProCURE, Catalan Institute of Oncology, Oncobell, Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, 08908, Barcelona, Catalonia, Spain.
  • García N; ProCURE, Catalan Institute of Oncology, Oncobell, Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, 08908, Barcelona, Catalonia, Spain.
  • Lorentzian A; Department of Pediatrics, University of British Columbia, Vancouver, BC, V6H 0B3, Canada.
  • Baiges A; ProCURE, Catalan Institute of Oncology, Oncobell, Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, 08908, Barcelona, Catalonia, Spain.
  • Blommaert E; ProCURE, Catalan Institute of Oncology, Oncobell, Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, 08908, Barcelona, Catalonia, Spain.
  • Gómez A; Department of Biosciences, Faculty of Sciences and Technology (FCT), University of Vic - Central University of Catalonia (UVic-UCC), Vic, 08500, Barcelona, Catalonia, Spain.
  • Mirallas O; ProCURE, Catalan Institute of Oncology, Oncobell, Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, 08908, Barcelona, Catalonia, Spain.
  • Garrido-Utrilla A; ProCURE, Catalan Institute of Oncology, Oncobell, Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, 08908, Barcelona, Catalonia, Spain.
  • Palomero L; ProCURE, Catalan Institute of Oncology, Oncobell, Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, 08908, Barcelona, Catalonia, Spain.
  • Espín R; ProCURE, Catalan Institute of Oncology, Oncobell, Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, 08908, Barcelona, Catalonia, Spain.
  • Extremera AI; ProCURE, Catalan Institute of Oncology, Oncobell, Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, 08908, Barcelona, Catalonia, Spain.
  • Soler-Monsó MT; Department of Pathology, University Hospital of Bellvitge, Oncobell, Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, 08908, Barcelona, Catalonia, Spain.
  • Petit A; Department of Pathology, University Hospital of Bellvitge, Oncobell, Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, 08908, Barcelona, Catalonia, Spain.
  • Li R; Department of Biochemistry and Molecular Medicine, School of Medicine and Health Sciences, The George Washington University, Washington, DC, 20037, USA.
  • Brunet J; Hereditary Cancer Program, Catalan Institute of Oncology, Girona Biomedical Research Institute (IDIBGI), 17190, Girona, Catalonia, Spain.
  • Chen K; Department of Pediatrics, University of British Columbia, Vancouver, BC, V6H 0B3, Canada.
  • Tan S; Terry Fox Laboratory, British Columbia Cancer Agency, Vancouver, BC, V5Z 1L3, Canada.
  • Eaves CJ; Terry Fox Laboratory, British Columbia Cancer Agency, Vancouver, BC, V5Z 1L3, Canada.
  • McCloskey C; Princess Margaret Cancer Research Centre, University Health Network, Toronto, ON, M5G 2M9, Canada.
  • Hakem R; Princess Margaret Cancer Research Centre, University Health Network, Toronto, ON, M5G 2M9, Canada.
  • Khokha R; Department of Medical Biophysics, Faculty of Medicine, University Health Network, University of Toronto, Toronto, ON, M5G 1L7, Canada.
  • Lange PF; Princess Margaret Cancer Research Centre, University Health Network, Toronto, ON, M5G 2M9, Canada.
  • Lázaro C; Department of Medical Biophysics, Faculty of Medicine, University Health Network, University of Toronto, Toronto, ON, M5G 1L7, Canada.
  • Maxwell CA; Department of Pathology, University of British Columbia, Vancouver, BC, V6T 1Z7, Canada.
  • Pujana MA; Michael Cuccione Childhood Cancer Research Program, British Columbia Children's Hospital, Vancouver, BC, V6H 3N1, Canada.
Nat Commun ; 13(1): 1895, 2022 04 07.
Article em En | MEDLINE | ID: mdl-35393420
ABSTRACT
Breast cancer risk for carriers of BRCA1 pathological variants is modified by genetic factors. Genetic variation in HMMR may contribute to this effect. However, the impact of risk modifiers on cancer biology remains undetermined and the biological basis of increased risk is poorly understood. Here, we depict an interplay of molecular, cellular, and tissue microenvironment alterations that increase BRCA1-associated breast cancer risk. Analysis of genome-wide association results suggests that diverse biological processes, including links to BRCA1-HMMR profiles, influence risk. HMMR overexpression in mouse mammary epithelium increases Brca1-mutant tumorigenesis by modulating the cancer cell phenotype and tumor microenvironment. Elevated HMMR activates AURKA and reduces ARPC2 localization in the mitotic cell cortex, which is correlated with micronucleation and activation of cGAS-STING and non-canonical NF-κB signaling. The initial tumorigenic events are genomic instability, epithelial-to-mesenchymal transition, and tissue infiltration of tumor-associated macrophages. The findings reveal a biological foundation for increased risk of BRCA1-associated breast cancer.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Proteínas da Matriz Extracelular / Receptores de Hialuronatos / Proteína BRCA1 Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Proteínas da Matriz Extracelular / Receptores de Hialuronatos / Proteína BRCA1 Idioma: En Ano de publicação: 2022 Tipo de documento: Article